Načítá se...
Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases
In the therapeutic approach to patients with antiphospholipid syndrome (APS) with thrombotic manifestations, oral vitamin K antagonists (VKA) remain the standard of care. However, the use of VKA is very often associated with inability to achieve a therapeutic dose even in patients maintaining nutrit...
Uloženo v:
| Vydáno v: | Reumatologia |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4967983/ https://ncbi.nlm.nih.gov/pubmed/27504026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/reum.2016.61217 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|